Skip to main content

Table 1 Patient demographics, clinical data and lab lymphocytes summary, by all and by pathology (tumor vs. non-tumor) at the second surgery

From: The predictive value of absolute lymphocyte counts on tumor progression and pseudoprogression in patients with glioblastoma

 

All Patients

(n = 78)

Non-Tumor

(n = 41)

Tumor

(n = 37)

P-value

Demographics

Age at diagnosis: median (range)

56 (44.25–63.5)

59 (51–65)

53 (38–60)

0.015994

Male: No. (%)

39 (50)

20 (48.78)

19 (51.35)

 

Race: No. (%)

   

0.046301

 White, non-Hispanic

74 (94.87)

41 (100)

33 (89.19)

 

 Black/African American, non-Hispanic

4 (5.13)

0 (0)

4 (10.81)

 

Clinical Data

Histology

   

0.652495

  Glioblastoma multiforme: No. (%)

74(94.87)

39(95.12)

35(94.59)

 

  Glioblastoma small cell variant: No. (%)

1(1.28)

1(2.44)

0(0)

 

  Glioblastoma with oligodendroglioma: No. (%)

1(1.28)

1(2.44)

0(0)

 

  Glioblastoma, small cell variant: No. (%)

1(1.28)

0(0)

1(2.7)

 

  High grade glioneuronal tumor: No. (%)

1(1.28)

0(0)

1(2.7)

 

Extent of surgical resection (N = 77)

   

0.040166

  biopsy

5(6.49)

0(0)

5(13.51)

 

  GTR

55(71.43)

32(80)

23(62.16)

 

  subtotal

17(22.08)

8(20)

9(24.32)

 

MGMT Methylation Status (N = 70)

   

1

  Methylated: No. (%)

21(30)

11(28.95)

10(31.25)

 

  Unmethylated: No. (%)

49(70)

27(71.05)

22(68.75)

 

KPS

85(80 ~ 90)

90(80 ~ 90)

80(70 ~ 90)

0.100858

Prior RT

   

0.046301

  No

74(94.87)

41(100)

33(89.19)

 

  Yes

4(5.13)

0(0)

4(10.81)

 

Prior chemo

   

0.221778

  No

76(97.44)

41(100)

35(94.59)

 

  Yes

2(2.56)

0(0)

2(5.41)

 

Prior immune suppression tx

   

1

  No

76(97.44)

40(97.56)

36(97.3)

 

  Yes

2(2.56)

1(2.44)

1(2.7)

 

Baseline steriod use (N = 76)

   

1

 No

38(50)

21(51.22)

17(48.57)

 

  Yes

38(50)

20(48.78)

18(51.43)

 

Treatment regimen

   

0.494838

  Concurrent RT/TMZ

76(97.44)

39(95.12)

37(100)

 

  RTonly

2(2.56)

2(4.88)

0(0)

 

Adjuvant Chemo

   

1

  No

1(1.28)

1(2.44)

0(0)

 

  Yes

77(98.72)

40(97.56)

37(100)

 

Infection

   

0.702159

  No

71(91.03)

38(92.68)

33(89.19)

 

  Yes

7(8.97)

3(7.32)

4(10.81)

 

Pathology at 2nd Surgery

   

0.000000

  mixed

29(37.18)

29(70.73)

0(0)

 

  necrosis/tx effect

12(15.38)

12(29.27)

0(0)

 

  tumor

37(47.44)

0(0)

37(100)

 

Laboratory Data

ALC_beforeRT (N = 75): median (range)

1.4 (0.9–1.9)

1.2 (0.9–1.9)

1.4 (0.9–2.3)

0.303656

ALC_postRT (N = 73): median (range)

0.9 (0.6–1.3)

1 (0.6–1.3)

0.9 (0.68–1.23)

0.742197

ALC_MRIProgression (N = 74): median

1 (0.7–1.5)

1 (0.72–1.5)

0.95 (0.7–1.62)

0.777925

Baseline CD4 counts (N = 14): median (range)

908 (619–1070.5)

1054 (888.25–1172.5)

763.5 (593.25–950)

0.217997

POST RT/Chemo CD4 count (N = 23): median (range)

344 (269.5–490.5)

404.5 (276.75–530.25)

344 (263–345)

0.377232

CD4 count_MRIProgression (N = 15): median (range)

340 (253–532)

484.5 (321–705.25)

253 (175–299.5)

0.048736